Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Actonel Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal Women

NCT00244907
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
Genistein vs Risedronate
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Effects on the Relative Bioavailability of Different Dosages of Risedronate

NCT00717145
View directory record Official record
Conditions
Postmenopausal, Non-lactating, Surgically Sterile
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children

NCT00106028
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
risedronate sodium (Actonel), Placebo
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
4 Years to 15 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
5
States / cities
Miami, Florida • Omaha, Nebraska • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional

Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer

NCT00054418
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium carbonate, vitamin D, risedronate sodium, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
198
States / cities
Mobile, Alabama • Scottsdale, Arizona • Aurora, Colorado + 124 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 27, 2026, 3:14 PM EDT
Terminated Phase 3 Interventional Results available

Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy

NCT00216060
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Christopher Sweeney, MBBS
Other
Eligibility
18 Years and older · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
31
States / cities
La Mesa, California • San Bernardino, California • New Britain, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly Risedronate

NCT00577720
View directory record Official record
Conditions
Postmenopausal Women
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
6
States / cities
Costa Mesa, California • Gainsville, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

NCT00541658
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
923 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Birmingham, Alabama • Oakland, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 4 Interventional Results available

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

NCT01709110
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Teriparatide, Risedronate, Placebo, Calcium, Vitamin D
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Female only
Enrollment
1,366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
30
States / cities
Birmingham, Alabama • Concord, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2019 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Not applicable Interventional

The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)

NCT00118508
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate (including placebo)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional

Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women

NCT00358176
View directory record Official record
Conditions
Osteoporosis Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older · Female only
Enrollment
1,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Oct 27, 2026, 3:14 PM EDT
Recruiting Phase 3 Interventional

Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

NCT04922333
View directory record Official record
Conditions
Bone Loss
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 4 Interventional

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

NCT00616694
View directory record Official record
Conditions
Osteoporosis
Interventions
Actonel
Drug
Lead sponsor
Sanofi
Industry
Eligibility
30 Years to 85 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 27, 2026, 3:14 PM EDT
Completed No phase listed Observational

Replication of the VERO Osteoporosis Trial in Healthcare Claims Data

NCT04879420
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Risedronate
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 120 Years · Female only
Enrollment
12,757 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 4 Interventional

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

NCT00130403
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
risedronate sodium
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis

NCT00619957
View directory record Official record
Conditions
Other Osteoporosis
Interventions
Placebo tablet, Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
30 Years and older · Male only
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Stuart, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2011 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

NCT00266708
View directory record Official record
Conditions
Renal Transplant Osteodystrophy
Interventions
Risedronate, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2019 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing Dosing Time and Calcium and Vitamin D on the Relative BA of 35 mg DR Risedronate Dosed With Food

NCT00868907
View directory record Official record
Conditions
Healthy
Interventions
35 mg risedronate DR tablet
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
4
States / cities
Gainesville, Florida • Miami, Florida • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 4 Interventional

Risedronate in the Prevention of Osteoporosis in Postmenopausal Women

NCT00402441
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate (HMR4003)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
45 Years and older · Female only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Heartland Osteoporosis Prevention Study

NCT02186600
View directory record Official record
Conditions
Osteopenia
Interventions
Calcium Carbonate, Vitamin D3, Risedronate, Bone-loading exercises
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 27, 2026, 3:14 PM EDT
Completed No phase listed Observational

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

NCT00778154
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Not listed
Lead sponsor
Warner Chilcott
Industry
Eligibility
Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Palm Desert, California • Lakewood, Colorado • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female Subjects

NCT00846196
View directory record Official record
Conditions
Osteoporosis
Interventions
risedronate DR (Phase III clinical supply), risedronate 35 mg DR (Commercial Tablet)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
San Diego, California • Fort Myers, Florida • Miramar, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

NCT00918749
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
150 mg, 75 mg, 100 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
6
States / cities
Daytona Beach, Florida • Fort Myers, Florida • Honolulu, Hawaii + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Oct 27, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT

NCT03861091
View directory record Official record
Conditions
Lung Neoplasm
Interventions
risedronate, Matching placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
High Point, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 27, 2026, 3:14 PM EDT